SCHEMBL6711945

SCHEMBL6711945

CC(C)(C)OC(=O)N1CCc2c(C=C[N+](=O)[O-])c3ccccc3n2CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
ALDH1A1 P00352 3/20 0.42
MAPT P10636 3/20 0.42
LMNA P02545 1/20 0.42
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HTR6 P50406 1/20 0.39
DTYMK P23919 1/20 0.38
CNR2 P34972 1/20 0.38
MET P08581 1/20 0.38
RAB9A P51151 1/20 0.37
TGM2 P21980 2/20 0.37
F13A1 P00488 1/20 0.37
TGM1 P22735 1/20 0.37
NR1H2 P55055 1/20 0.37
GRM5 P41594 1/20 0.37
GPR119 Q8TDV5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6711942 1.00 CHRM2 (0.44) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL6710978 0.84 HTR2A (0.50) CHRM2CHRM4CHRM1CHRM3LMNA
SCHEMBL6712576 0.72 HTR2A (0.67) ALDH1A1MAPTLMNAHTR6
SCHEMBL30412877 0.70 MAPT (0.55) ALDH1A1MAPTLMNARAB9A
SCHEMBL20424957 0.70 MAPT (0.55) ALDH1A1MAPTLMNARAB9A
SCHEMBL4401695 0.70 NR1H2 (0.58) ALDH1A1MAPTLMNAMETTGM2
SCHEMBL613287 0.69 CHRM2 (0.49) CHRM2CHRM4CHRM1CHRM3HDAC1
SCHEMBL614943 0.67 HTR2A (0.53) CHRM2CHRM4CHRM1CHRM3HDAC1
SCHEMBL6715677 0.66 HTR2A (0.53) CHRM2CHRM4CHRM1CHRM3NR1H2
SCHEMBL20503370 0.66 MAPT (0.49) ALDH1A1MAPTLMNANR1H2GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US disclosed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US disclosed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HTR1D, HTR1A, HTR1E CHRM2 629/4885CHRM4 238/4885CHRM1 236/4885
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HCRTR2, NR2C2, RCOR3 CHRM2 93/4885CHRM4 100/4885CHRM1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.